Stason to sell Unitract safety syringe to drugmakers in Asia

By Gareth Macdonald

- Last updated on GMT

Related tags Hypodermic needle Injection Pharmacology

Stason Pharmaceuticals’ subsidiary Standard Chem and Pharm will act as primary distributor for the Unitract 1ml safety syringe in China, Japan and Taiwan under a five-year new deal with US delivery device maker Unilife.

US based Stason has agreed to buy at least one million of the syringes a year for supply to the named territories, replacing the Shanghai Kindly Enterprise Development group (KDL), whose distribution deal with Unilife has expired.

KDL will continue provide to provide assembly services for the product within China on a per order basis, although Stason has indicated “a preference to receive units… that are assembled at Unilife's​” manufacturing facilities in Pennsylvania.

Asian Demand

The syringe, which Unilife claims is the only one of its kind to allow the user to control the speed of needle retraction, is designed to minimise the risk of needle stick injuries and reuse.

And, while such issues are a concern worldwide, in a region like Asia with high HIV and HCV rates they are a particularly large problem according to Unilife CEO Alan Shortfall.

Shortfall explained that: “We believe there is a significant market opportunity for our safety syringes throughout the Asia-Pacific region… [where there is] a desire to use premium safety medical devices that can minimize the transmission of blood-borne pathogens​.”

He also said that Unilife is “continuing to negotiate with other pharmaceutical and healthcare companies across the world for distribution rights for the Unitract,” but did not provide specific details of the discussions​.”

Stason CEO Harry Fan was also upbeat about, commenting that” there are significant opportunities for pharmaceutical companies to gain a competitive market advantage by supplying their injectable drugs in kits containing the drug vial and units of the Unitract​.”

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 09-Jun-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Related suppliers